In Ongoing Adalimumab Litigation With Coherus, Amgen Denies Patent Infringement The Center for Biosimilars
Amgen has now answered Coherus BioSciences’ complaint and denies that it has infringed on Coherus’ patents. Amgen also said that the patents are invalid for …